Kevin Spencer a, *, Kypros H. Nicolaides b. BJOG: an International Journal of Obstetrics and Gynaecology March 2003, Vol. 110, pp.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Kevin Spencer a, *, Kypros H. Nicolaides b. BJOG: an International Journal of Obstetrics and Gynaecology March 2003, Vol. 110, pp."

Transcription

1 BJOG: an International Journal of Obstetrics and Gynaecology March 2003, Vol. 110, pp Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience Kevin Spencer a, *, Kypros H. Nicolaides b Objective To evaluate the performance of screening for fetal trisomy 21 in the first trimester of twin pregnancies by a combination of maternal serum biochemistry and ultrasonography. Design Three year retrospective review of screening performance. Setting District General Hospital maternity unit. Population All women booked to receive routine antenatal care at Harold Wood Hospital between 1 June 1998 and 30th September The population included 13,940 women of all ages presenting with pregnancies between 10 weeks 3 days and 13 weeks 6 days gestation. Of these, 230 had a twin pregnancy. Methods Women booked into the clinic were offered screening using a combination of maternal serum free h-hcg and pregnancy-associated plasma protein-a (PAPP-A) and fetal nuchal translucency thickness. Women at increased risk of carrying a fetus with trisomy 21 or trisomy 13/18 (1 in 300 at sampling) were offered counselling and an invasive diagnostic procedure. Follow up of the outcome of all pregnancies was carried out. For women who on examination were at 14 weeks of gestation or greater, or for women presenting as late bookers beyond 14 weeks, screening was performed in the same time frame using only maternal serum free h-hcg and a-fetoprotein. Main outcome measures The first trimester detection rate for trisomy 21 and all aneuploides, false positive rate, uptake of screening, uptake of invasive testing in women identified at increased risk and fetal loss rates after invasive testing. Results Overall, 97.4% of the women with twins (224/230) accepted first trimester screening. The rate of detection of trisomy 21 was 75% (3/4). Fetal death at presentation was found in 3.4% of fetuses (16/460). Of women who accepted screening, 4.3% (10/230) presented too late for fetal nuchal translucency measurement and 10.0% of women (23/230) presented too early. A risk for trisomy 21 was calculated for each fetus based on the individual fetal nuchal translucency thickness and the maternal biochemistry. The false positive rate among those eligible for first trimester screening was 9.0% (19/206) of pregnancies and 6.9% of fetuses (28/412). Uptake of invasive testing was 59% (10/17) with chorionic villus sampling in eight cases and amniocentesis in two. No fetal loss occurred within 28 days of chorionic villus sampling and no loss occurred after amniocentesis. One case of trisomy 21 was identified for every three invasive procedures. Conclusion First trimester screening for trisomy 21 in twin pregnancies is both theoretically possible and practically achievable using a combination of nuchal translucency thickness and maternal serum biochemistry. However, dilemmas for the mother and health professionals when both nuchal translucency thickness measurements are normal might suggest that greater reliance be placed on the nuchal translucency thickness risk alone when counselling women about invasive testing. IRODUCTION In the first trimester of pregnancy, screening by a combination of fetal nuchal translucency thickness and a Department of Clinical Biochemistry, Harold Wood Hospital, Romford, Essex, UK b Harris Birthright Research Centre for Fetal Medicine, King s College Hospital, London, UK * Correspondence: Dr K. Spencer, Department of Clinical Biochemistry, Harold Wood Hospital, Gubbins Lane, Romford, Essex RM3 0BE, UK. D RCOG 2003 BJOG: an International Journal of Obstetrics and Gynaecology doi: /s (02) maternal serum free h-human chorionic gonadotrophin (h-hcg) and pregnancy-associated plasma protein-a (PAPP-A) has been shown in retrospective 1 and prospective studies 2,3 to identify approximately 90% of cases of trisomy 21 in singleton pregnancies for a 5% false positive rate. The incidence of twin pregnancy is increasing in the UK, partly as a result of the increased use of assisted reproductive techniques. Furthermore, the pregnancy population is getting older and the rate of twinning increases with maternal age. In 1979, the incidence of multiple pregnancies was 0.97%, this has increased to 1.43% by In the second trimester, biochemical screening of twin

2 SCREENING FOR TRISOMY 21 IN TWINS 277 pregnancies was shown to be possible using a pseudo risk approach 5,6. The detection rate in twins discordant for trisomy 21 was expected to be lower than in singleton pregnancies. Nevertheless, this approach identified twins concordant for trisomy 21 in prospective screenings 7. In the first trimester, both fetal nuchal translucency thickness 8 and maternal serum biochemistry can be combined together 9 to provide detection rates approaching those achieved in singleton pregnancies. Such algorithms do not seem to be dependent upon chorionicity 10 and an example case of twins discordant for trisomy 21 that had been identified by prospective screening has been described 11. Screening of twin pregnancies is, however, still considered by many to be problematical because of the significant clinical, technical and ethical challenges posed for the diagnosis and clinical management of such pregnancies 6,12,13. Here we examine the outcome of screening or trisomy 21 in the first trimester of twin pregnancies over a three-year period in our OSCAR clinic 2,3. METHODS The maternity unit under study is located in the borough of Havering at the eastern boundary of Greater London. The screening population is predominantly white Caucasian from the London Borough of Havering (84.2% with an RM postcode) and the Local Authority of Brentwood (13.2% with a CM postcode), with a small proportion of women from the London Borough of Barking and Dagenham (2.3% with an IG postcode) and 0.3% from other adjacent areas. The two major areas comprise a relatively affluent population with approximately half the population in social class I or II. The 2000 Index of Multiple Deprivation provided by the Department of Environment, Transport and the Regions 14 showed Havering with a rank of 233/354 districts in England and Wales, while that of Brentwood was 311/354. Barking and Dagenham on the other hand has a higher proportion of manual skilled, partly skilled and unskilled workforce. The Index of Multiple Deprivation in this Borough was ranked 24/354, showing considerably higher deprivation. All women booked for maternity care at Harold Wood Hospital, Essex are given an appointment to attend the antenatal clinic for the first time at around 12 weeks. Screening using the first trimester one-stop approach began in June In the first year of screening, the qualifying gestational age was between 10 weeks 3 days and 13 weeks 6 days by ultrasound dating. During the second and third year, the minimum gestation was increased to 11 weeks 0 days to allow for better identification of structural anomalies at the slightly later gestations. Women are initially seen in the community by a member of the community midwifery team (65% of cases) and they receive an information leaflet about the one-stop clinic service and the screening tests that are available with their initial booking appointment letter. On attending the clinic at a specified appointment time, women have a consultation with a midwife concerning the available tests and, if they elect to have prenatal screening for chromosomal anomalies, all relevant clinical information is recorded on the request forms. After pre-test counselling, women opting into the screening programme go to the phlebotomy room where blood samples are taken for serum biochemical screening, in addition to samples for other routine antenatal investigations. Prenatal screening blood samples are passed through to the adjacent clinic laboratory and the women then move on to the ultrasound suite where fetal nuchal translucency thickness and crown rump length are measured using standard procedures 16 ( by sonographers certified by the Fetal Medicine Foundation. At the same time, a mini anomaly scan is also performed. The whole ultrasound process can be completed within a 20-minute period in 99% of the cases. All relevant clinical information is recorded on a networked fetal database (ViewPoint, Webling, Germany). If the ultrasound dating reveals the fetus has a gestation prior to 11 weeks (45 mm crown rump length 38 mm in year one), then the mother is sent back to the reception to be rebooked at the appropriate period. If the gestation is beyond 13 weeks 6 days (84 mm by crown rump length), then the laboratory is informed and a-fetoprotein is measured instead of PAPP-A. During the time the mother is in the ultrasound suite, the serum from the blood sample is separated and analysed for free h-hcg and PAPP-A using the Kryptor analyser (Brahms Diagnostica, Berlin formerly CIS) in the clinic laboratory. The quality performance of this system has previously been described 1,17. When the results are available (within 20 minutes) these are logged onto the fetal database and a composite risk report is produced by the time the woman has returned from the ultrasound suite. This risk report is then available for the midwife/counsellor to discuss with the woman. Appropriate, further follow up and management is arranged. Patient-specific risks were calculated by a multivariate approach using populations parameters established in our retrospective study 1, after correction of the maternal serum biochemistry for maternal weight 18 and for twin pregnancies 10, and the age-related risk of the trisomy in singleton pregnancies at the time of sampling 19,20. Although we have previously shown that in the first trimester free h-hcg levels are significantly increased (21%) in singleton pregnancies achieved by assisted reproduction 21, no correction was made for this as no data have been published in twin pregnancies. Similarly, although the incidence of raised nuchal translucency thickness is higher in monochorionic twins than in dichorionic twins 8, an appropriate correction algorithm has yet to be developed. Women with an increased risk in either fetus (1 in 300) for trisomy 21 are referred to the Harris Birthright Centre for Fetal Medicine for chorionic villus sampling or

3 278 K. SPENCER & K.H. NICOLAIDES Table 1. Risk and in twins when the mother declined invasive testing. Case Risk fetus 1 Risk fetus 2 fetus 1 fetus amniocentesis and fetal karyotyping. Provisional results from quantitative PCR were available within 48 hours and a confirmed diagnosis by conventional karyotyping within seven days. Outcome of all pregnancies was ascertained from delivery room records, hospital PAS system and Child Health records and was cross checked with the fetal database. Cytogenetics records were obtained from the laboratory, the Child Health computer records and the National Down s Syndrome register. RESULTS Within a three-year and four-month period (1st June 1998 to 30th September 2001), a total of 13,940 pregnant women were offered first trimester screening in the OSCAR clinic. Of these 230 cases were twin pregnancies (1.65%) of which 21% were conceived by assisted conception. The uptake of first trimester screening among women with a twin pregnancy was 97.4% (224/230). The population consisted of 84% Caucasian, 2% Afro-Caribbean, 3% Asian and 11% of either unknown or other ethnic origin. The median gestational age was 12 weeks 1 day (range 10 weeks 4 days to 13 weeks 6 days) and median crown rump length was 59 mm (range 38 84). The median maternal age was 31.5 years (range ). The median maternal weight of the population was 66 kg (range ). Cigarette smoking was self-reported in 18.3%, with 80.2% reporting themselves as non-smokers and the status was unknown in 1.5% of cases. Fetal death was noted on ultrasound examination in 3.4% of fetuses (16/460). According to the measurement of fetal crown rump length, the gestation was prior to the minimum acceptable period in 10% of cases (23/230); these women were rebooked for repeat examination at the appropriate gestation. In addition, 4.3% of women (10/230) had a gestation too late for nuchal translucency thickness measurement and these women had conventional second trimester screening 22 with a-fetoprotein and free h-hcg. In total, after exclusion of those women with fetal demise at presentation, those declining screening and those with crown rump length beyond 84 mm, some 206 with a twin pregnancy had first trimester screening performed. Of the twin fetuses screened in the OSCAR clinic, 6.8% (28/412) had risks greater than the 1 in 300 cutoff and 9.2% of pregnancies (19/206) had at least one fetus with an increased risk. After counselling, 37% of women (7/19) declined the offer of an invasive diagnostic test, while 63% (12/19) accepted invasive testing. Chorionic villus sampling was the procedure chosen by 83% of women (10/12) requesting invasive testing while 17% (2/12) decided to wait until 14 weeks for amniocentesis. In all cases of invasive testing when the fetus was shown to be of normal karyotype, the pregnancy continued with a viable fetus at least beyond 28 days after the procedure. The individual combined risks and the fetal nuchal translucency thickness in those women declining invasive testing are shown in Table 1, indicating a predominance of women with risks very close to the cutoff and with normal nuchal translucency thickness in both fetuses. Among the twin study population, four cases with trisomy 21 were ascertained (Table 2). A combination of maternal age, fetal nuchal translucency thickness, maternal serum free h-hcg and PAPP-A identified 75% (3/4) cases with trisomy 21. There was one case of trisomy 21 detected per three invasive procedures. All women with an identified fetus with trisomy 21 elected to undergo embryo reduction, which was carried out by ultrasound-guided injection of potassium chloride in the chest of the affected fetus. In each of the three cases, the surviving twin progressed to a normal healthy delivery. Table 3 provides a brief summary of the obstetric history to each case. Among the 19 women identified at increased risk, in addition to the three cases with trisomy 21, fetal death occurred in two sets of twins at 24 weeks. In one of these, Table 2. Cases of twins discordant for trisomy 21. Case Maternal age (years) Gestation (week þ day) Chorionicity 1 2 risk 1 risk 2 Free PAPP-A Biochemical Combined Combined Outcome Outcome h-hcg risk risk 1 risk þ 5 Dichorionic diamniotic N T þ 2 Dichorionic diamniotic N T þ 5 Dichorionic diamniotic N T þ 1 Dichorionic diamniotic N T21

4 SCREENING FOR TRISOMY 21 IN TWINS 279 Table 3. Obstetric history of twin pregnancies discordant for trisomy 21. ICSI ¼ intracytoplasmic sperm injection. Case Gravidity Parity IUD <15 weeks Conception Smoker Normal No Normal No Normal No ICSI No twin-to-twin transfusion had occurred. In one further case, preterm delivery occurred at 26 weeks with neither twin surviving, and in yet a further case, one of the twins had a missing hand. The median free h-hcg after weight correction and before correction for twin pregnancy was 2.15 with a mean log 10 of and a log 10 standard deviation of The median PAPP-A after weight correction and before correction for twin pregnancy was 1.93 with a mean log 10 of and a log 10 standard deviation of These values are very similar to those published in a previous series 9. DISCUSSION The prevalence of twin pregnancies increases with maternal age. In addition to being twice at risk of structural defects, one would expect the risk for chromosomal abnormalities to be higher than in singletons 23. However, when congenital malformation rates in twins have been studied, it has been difficult to demonstrate this for trisomy 21 and some studies have reported a lower rate of trisomy 21 in twins compared with singletons 24. The difficulty with such studies is related to population size, as the incidence of twins is only 15 per 1000 births, even the largest study only included 42 cases with trisomy 21. In the second trimester, maternal serum biochemical markers on average appear twice as high in twins compared with that of a singleton pregnancy at the same gestational age 5,6,25. Using the pseudo risk approach correcting for twins 5, the provision of risks in twin pregnancies leads to detection rates in twins some 15% lower than in singleton pregnancies 6,25. Although such approaches have been successful in routine practice 7, many centres still consider the ethical and technical difficulties too problematical in routine obstetric units 13. As a consequence, many do not offer screening in twin pregnancies. In the first trimester, the use of individual nuchal translucency thickness has allowed the calculation of specific risks for each fetus. This physical marker can specifically identify the fetus at increased risk 8 and thus be used as a guide when undertaking chorionic villus sampling and selective fetocide in twins discordant for trisomy 21. In addition, it has been suggested that the risk based on nuchal translucency thickness and maternal age can be used as the basis for making decisions regarding the appropriate diagnostic procedure to be followed in such circumstances 26. The projected detection rate using fetal nuchal translucency thickness and maternal age alone was 75.2%, although this did not take into account chorionicity, in which the incidence of increased nuchal translucency thickness is 1.5 times greater in monochorionic than in dichorionic twins 8. Levels of first trimester maternal serum biochemical makers are similarly on average twice as high in twins than in singleton pregnancies of the same gestation 9. Using a pseudo risk approach, combining fetal nuchal translucency thickness and maternal serum biochemistry was predicted to identify 80% of cases of twins discordant for trisomy 21 (at a 5% false positive rate) and 81.5% in concordant twins. Thus, it was argued that while maternal serum biochemistry alone could not specifically identify the fetus at risk in the presence of twins discordant for trisomy 21, it would be possible to enhance the detection rate in twins by some 5 6% yet still retain the benefits of nuchal translucency thickness in identifying the specific affected twin 9. Furthermore, it has been shown that chorionicity has no impact on the maternal serum biochemical marker levels in twin pregnancy 10. The first practical example of this new first trimester twin algorithm was presented in a report 11 of the first case in Table 2. In this paper, we have outlined our first 3.3 years experience in screening twin pregnancies. Our incidence of twin pregnancies is a little above the national average but not greatly so. However, our incidence of twins discordant for trisomy 21 is far greater than one might have expected (1 in 58); based on the maternal age distribution of our twin pregnancies and the risk of trisomy 21 in singleton pregnancies at 12 weeks of gestation, we would have expected to see 1.5 fetuses with trisomy 21 rather than 4. Our detection of 75% of cases (3/4) is in line with our theoretical projection. The rate of acceptance of first trimester screening among twin pregnancies was no different from that observed in singleton pregnancies in which a very high uptake was achieved 3. Fetal death was twice as common among twin pregnancies than in our singleton series, reflecting the increased perinatal mortality in multiple pregnancy. Uptake of invasive testing was lower than in the case with singleton pregnancies 3 when 80% of women accept invasive testing. This reflects both the added risk and complexity of the invasive procedure in twins and the increased potential fetal loss of the normal twin as a result of selective fetocide. Clearly, instances when nuchal translucency thickness is normal in both twins, yet the biochemistry is abnormal, present a further dilemma in that even if chorionic villus sampling was performed on both twins fetal reduction would be inadvisable as it would be difficult to identify the affected twin. Although adding maternal serum biochemistry does improve detection, clearly, nuchal translucency thickness risk alone is the

5 280 K. SPENCER & K.H. NICOLAIDES predominant factor by which women should be counselled regarding invasive testing. Acknowledgements The OSCAR clinic is a multidisciplinary clinic which functions because of the dedication of all contributors to the team. The authors would like to thank the support and contributions from all those in midwifery, obstetrics, clerical, sonography, pathology and support workers. References 1. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at weeks using fetal nuchal translucency, maternal serum free h-human chorionic gonadotropin and pregnancy associated plasma protein-a. Ultrasound Obstet Gynecol 1999;13: Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies; a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 2000;107: Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 2003;110: Office of National Statistics. Birth Statistics, Series FM1 No. 29. London: HMSO, Wald N, Cuckle H, Hu T, George L. Maternal serum unconjugated oestriol and human chorionic gonadotropin levels in twin pregnancies: implications for screening for Down s Syndrome. Br J Obstet Gynaecol 1991;98: Spencer K, Salonen R, Muller F. Down s syndrome screening in multiple pregnancies using alpha fetoprotein and free beta hcg. Prenat Diagn 1994;14: Verdin SM, Braithwaite JM, Spencer K, Economides DL. Prenatal diagnosis of trisomy 21 in monozygotic twins with increased nuchal translucency and abnormal serum biochemistry. Fetal Diagn Ther 1997;12: Sebire NJ, Snijders RJM, Hughes K, Sepulveda W, Nicolaides KH. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at weeks of gestation. Br J Obstet Gynaecol 1996;103: Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free h-hcg and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 2000;20: Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free h-hcg or PAPP-A levels. Prenat Diagn 2001;21: Spencer K, Nicolaides KH. First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free h-hcg and PAPP-A. Prenat Diagn 2000;20: Reynolds TM. Down s syndrome screening in twin pregnancies. Prenat Diagn 1995;15: Cuckle H. Down s syndrome screening in twins. JMedScreen 1998;5: Spencer K. Near patient testing and Down s syndrome screening. Proc UK NEQAS 1998;3: Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at weeks of gestation. Lancet 1999;18: Spencer K. Evaluation of effect of analytical imprecision in maternal serum screening for Down s syndrome. Ann Clin Biochem 2001;38: Spencer K, Ong CYT, Liao AWJ, Nicolaides KH. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 2000;20: Snijders RJM, Sebire NJ, Nicolaides KH. Maternal age and gestational age specific risks for chromosomal defects. Fetal Diagn Ther 1995; 10: Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age and gestation specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999;13: Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. Firsttrimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 2001;10: Spencer K. Second trimester prenatal screening for Down s syndrome using a-fetoprotein and free h-hcg: a seven year review. Br J Obstet Gynaecol 1999;106: Baldwin VJ. Anomalous development in twins. In: Baldwin VJ, editor. Pathology of Multiple Pregnancy. New York: Springer-Verlag, 1994: Doyle PE, Beral V, Botting B, Wale CJ. Congenital malformations in twins in England and Wales. J Epidemiol Community Health 1990;45: Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple maker screening for Down Syndrome in twin pregnancies. Prenat Diagn 1996;16: Sebire NJ, Noble PL, Psarra A, Papapanagiotou G, Nicolaides KH. Fetal karyotyping in twin pregnancies: selection of technique by measurement of fetal nuchal translucency. Br J Obstet Gynaecol 1996;103: Accepted 11 November 2002

Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester

Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester PRENATAL DIAGNOSIS Prenat Diagn 2000; 20: 390±394. Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester Kevin Spencer 1 *, Natasha Tul 2 and Kypros H. Nicolaides 2

More information

Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hcg and PAPP-A at 11 + 0to13+ 6 weeks

Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hcg and PAPP-A at 11 + 0to13+ 6 weeks Ultrasound Obstet Gynecol 2006; 27: 151 155 Published online 30 December 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.2699 Screening for trisomy 21 by fetal tricuspid regurgitation,

More information

Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at weeks of gestation

Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at weeks of gestation PRENATAL DIAGNOSIS Prenat Diagn 2007; 27: 849 853. Published online 25 June 2007 in Wiley InterScience (www.interscience.wiley.com).1793 Dose dependency between cigarette consumption and reduced maternal

More information

Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers

Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers DOI: 10.1002/pd.4019 ORIGINAL ARTICLE Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers Kevin Spencer* and Nicholas J. Cowans

More information

A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester

A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester Ultrasound Obstet Gynecol 2011; 37: 38 47 Published online 7 December 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.8845 A reassessment of biochemical marker distributions in

More information

Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation

Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation American Journal of Obstetrics and Gynecology (2006) 194, 397 401 www.ajog.org Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation Aris T. Papageorghiou, MD, a Kyriaki Avgidou, MD, a

More information

Correspondence: Dr K. Spencer, Endocrine Unit, Clinical Biochemistry Department, Harold Wood Hospital, Gubbins Lane, Romford, Essex, RM3 0BE, UK

Correspondence: Dr K. Spencer, Endocrine Unit, Clinical Biochemistry Department, Harold Wood Hospital, Gubbins Lane, Romford, Essex, RM3 0BE, UK Ultrasound Obstet Gynecol 1999;:231 237 A screening program for trisomy 21 at 10 14 using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-a

More information

Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow

Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow Ultrasound Obstet Gynecol 1998;12:380 384 Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow A. Matias*, C. Gomes*, N. Flack*, N. Montenegro and K. H. Nicolaides*

More information

Incorporating DNA sequencing into current prenatal screening practice for Down s syndrome

Incorporating DNA sequencing into current prenatal screening practice for Down s syndrome 1 Incorporating DNA sequencing into current prenatal screening practice for Down s syndrome Nicholas J Wald FRS* Wolfson Institute of Preventive Medicine Barts and the London School of Medicine and Dentistry

More information

Frontomaxillary and mandibulomaxillary facial angles at 11 + 0to13+ 6 weeks in fetuses with trisomy 18

Frontomaxillary and mandibulomaxillary facial angles at 11 + 0to13+ 6 weeks in fetuses with trisomy 18 Ultrasound Obstet Gynecol 2007; 30: 928 933 Published online 1 November 2007 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.2/uog.5188 Frontomaxillary and mandibulomaxillary facial angles

More information

Charts of fetal size: limb bones

Charts of fetal size: limb bones BJOG: an International Journal of Obstetrics and Gynaecology August 2002, Vol. 109, pp. 919 929 Charts of fetal size: limb bones Lyn S. Chitty a, *, Douglas G. Altman b Objective To construct new size

More information

Information for Your Patients

Information for Your Patients Information for Your Patients What is first trimester risk assessment for Down syndrome? First trimester screening for Down syndrome, also known as nuchal translucency screening, is a test offered to women

More information

Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin Pregnancies

Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin Pregnancies Original Paper Received: September 12, 2013 Accepted after revision: October 21, 2013 Published online: November 15, 2013 Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin Pregnancies

More information

cfdna in maternal plasma obtained from a population undergoing routine screening at 11-13 weeks gestation.

cfdna in maternal plasma obtained from a population undergoing routine screening at 11-13 weeks gestation. Reports of Major Impact www.ajog.org Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population Kypros H. Nicolaides, MD; Argyro Syngelaki, RM; Ghalia Ashoor, MD;

More information

The 11 13 +6 weeks scan

The 11 13 +6 weeks scan The 11 13 +6 weeks scan Kypros H. Nicolaides The 11 13 +6 weeks scan Fetal Medicine Foundation, London 2004 Dedication to Herodotos & Despina Contents Introduction 1. First trimester diagnosis of chromosomal

More information

Clinical Studies Abstract Booklet

Clinical Studies Abstract Booklet Clinical Studies Abstract Booklet The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) that assesses the risk of trisomies by analyzing cell-free DNA (cfdna) in maternal blood. Since January

More information

First Trimester Screening for Down Syndrome

First Trimester Screening for Down Syndrome First Trimester Screening for Down Syndrome What is first trimester risk assessment for Down syndrome? First trimester screening for Down syndrome, also known as nuchal translucency screening, is a test

More information

The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report

The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report 0 The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report Joan K Morris, Elizabeth De Souza December 2009 National Down Syndrome Cytogenetic Register Queen Mary University

More information

Prenatal screening and diagnostic tests

Prenatal screening and diagnostic tests Prenatal screening and diagnostic tests Contents Introduction 3 First trimester routine tests in the mother 3 Testing for health conditions in the baby 4 Why would you have a prenatal test? 6 What are

More information

Non-Invasive Prenatal Testing (NIPT) Factsheet

Non-Invasive Prenatal Testing (NIPT) Factsheet Introduction NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, is a new option in the prenatal screening and testing paradigm for trisomy 21 and a few other fetal chromosomal aneuploidies.

More information

Genetic Screening and Pregnancy: Selecting the Best Test for Your Patient

Genetic Screening and Pregnancy: Selecting the Best Test for Your Patient Genetic Screening and Pregnancy: Selecting the Best Test for Your Patient Britton Rink, MD, MS The Ohio State University Division of Maternal Fetal Medicine ACOG Practice Bulletin January 2007 Screening

More information

Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment

Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment Original Article Ann Clin Biochem 2001; 38: 230±234 Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment S N Millner From the Department of Pathology, University of

More information

Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies

Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies Ultrasound Obstet Gynecol 2013; 42: 34 40 Published online 7 June 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.12504 Implementation of maternal blood cell-free DNA testing in

More information

Risk Calculation Software Requirements for Down's Syndrome Screening

Risk Calculation Software Requirements for Down's Syndrome Screening Screening Programmes Fetal Anomaly Risk Calculation Software Requirements for Down's Syndrome Screening Version 1 January 2013 Created by: Dave Wright, Barry Nix, Steve Turner, David Worthington and Andy

More information

Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method

Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method Ghalia ASHOOR 1, Argyro SYNGELAKI 1, Eric WANG 2, Craig STRUBLE 2, Arnold OLIPHANT 2,

More information

fi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...

fi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас... АВАВАКдлАмА дла длама АсАядлАмА АВА АсдлАя & MАядлдлАмАК TА. 4, T. 2, АВ. 113-118, 2005 fi АУ : Аяapplefi. fiapple АсА» Ас Ам, длappleapple Ас..., Ая: Аяapplefi. fiapple, АВАУ Ас, АсА» Ас Ам длappleapple

More information

Prenatal Testing Special tests for your baby during pregnancy

Prenatal Testing Special tests for your baby during pregnancy English April 2006 [OTH-7750] There are a number of different prenatal (before birth) tests to check the development of your baby. Each test has advantages and disadvantages. This information is for people

More information

Assessment of Fetal Growth

Assessment of Fetal Growth Assessment of Fetal Growth Unit / Trust: 1. INTRODUCTION The aim of this guideline template is to outline the methods used to assess fetal growth and the referral pathways utilising customised antenatal

More information

Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies

Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies Susan S. Garfield, DrPH; Shannon O. Armstrong, BA Summary Background:

More information

Objectives. Disclosures 4/22/2012. Next-Gen DNA Sequencing in Prenatal Screening for Down Syndrome: How is it best used? Barbara M.

Objectives. Disclosures 4/22/2012. Next-Gen DNA Sequencing in Prenatal Screening for Down Syndrome: How is it best used? Barbara M. Next-Gen DNA Sequencing in Prenatal Screening for Down Syndrome: How is it best used? Barbara M. O Brien, MD Women & Infants Hospital Alpert Medical School of Brown University Providence, RI Women & Infants

More information

your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.

your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. Accurate answers about your baby s health simply, safely, sooner. What is the verifi Prenatal

More information

Increased fetal nuchal translucency at 11 14 weeks

Increased fetal nuchal translucency at 11 14 weeks PRENATAL DIAGNOSIS Prenat Diagn 2002; 22: 308 315. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/ pd.308 Increased fetal nuchal translucency at 11 14 weeks Kypros H.

More information

LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD

LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD 2 Outline Genetics 101: Basic Concepts and Myth Busting Inheritance Patterns

More information

The California Prenatal Screening Program

The California Prenatal Screening Program The California Prenatal Screening Program Provider ook netic Disease Screening Program Quad Marker Screening Serum Integrated Screening Full Integrated Screening TABLE OF CONTENTS WELCOME to the California

More information

Gutenberg Center in MALAGA

Gutenberg Center in MALAGA Introduction Gutenberg Center in MALAGA Gutenberg Center in Málaga opened in 1987 as a clinic to provide integral assisstance for women, divided into 6 Units, specialized in the different aspects of Obs

More information

Obstetrical Ultrasound and Prenatal Diagnostic Center

Obstetrical Ultrasound and Prenatal Diagnostic Center Obstetrical Ultrasound and Prenatal Diagnostic Center Prenatal Diagnosis: Options and Opportunities Learn about various screening options including Early Risk Assessment (ERA), now available to women of

More information

Ultrasound evaluation of fetal gender at 12 14 weeks

Ultrasound evaluation of fetal gender at 12 14 weeks Ultrasound evaluation of fetal gender at 12 14 weeks Marek Lubusky a,b, Martina Studnickova a, Ales Skrivanek a, Katherine Vomackova c, Martin Prochazka a Aims. The aim of this study was to assess the

More information

The First Trimester Screening program

The First Trimester Screening program The First Trimester Screening program The Fetal Medicine Foundation This guide has been designed to highlight the important clinical aspects of using the First Trimester Screening program. It is not intended

More information

Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA

Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013

More information

FIGO Good Practice Advice

FIGO Good Practice Advice FIGO Good Practice Advice 1. Screening for chromosomal abnormalities and non invasive prenatal diagnosis and testing Universal screening is a strategy applied to all individuals of a certain category to

More information

Neural tube defects: open spina bifida (also called spina bifida cystica)

Neural tube defects: open spina bifida (also called spina bifida cystica) Screening Programmes Fetal Anomaly Neural tube defects: open spina bifida (also called spina bifida cystica) Information for health professionals Publication date: April 2012 Review date: April 2013 Version

More information

Trisomy 13 (also called Patau s syndrome or T13)

Trisomy 13 (also called Patau s syndrome or T13) Screening Programmes Fetal Anomaly Trisomy 13 (also called Patau s syndrome or T13) Information for parents Publication date: April 2012 Review date: April 2013 Version 2 117 Information sheet to help

More information

Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies

Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies No. 261 (Replaces No. 187, February 2007) Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies This clinical practice guideline has been prepared by the Genetics Committee of the Society of

More information

The quadruple test screening for Down s syndrome and spina bifida

The quadruple test screening for Down s syndrome and spina bifida The quadruple test screening for Down s syndrome and spina bifida This leaflet provides information about a blood test to check for Down s syndrome and spina bifida. This test is available to you between

More information

Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA

Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST

More information

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register 1 Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register Joanne Gunby, M.Sc. CARTR Co-ordinator Email: gunbyj@mcmaster.ca Supported by the IVF Directors Group of

More information

Non-invasive prenatal testing. Contents:

Non-invasive prenatal testing. Contents: february 2014 A REGULAR CASE-BASED SERIES ON PRACTICAL PATHOLOGY FOR GPs Contents: What is non-invasive prenatal testing? Screening test vs diagnostic tests Case studies Who should be offered NIPT? Non-invasive

More information

journal of medicine The new england First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome abstract

journal of medicine The new england First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome abstract The new england journal of medicine established in 1812 november 10, 2005 vol. 353 no. 19 First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome Fergal D. Malone, M.D., Jacob A. Canick,

More information

Prenatal Screening Policies in Europe

Prenatal Screening Policies in Europe Prenatal Screening Policies in Europe 2010 EUROCAT Central Registry Room 12L09, University of Ulster Newtownabbey, Co Antrim Northern Ireland, BT37 0QB Tel: +44 (0)28 90366639 Fax: +44 (0)28 90368341 Email:

More information

Patient Education. intermountainhealthcare.org. A Guide to Prenatal Testing LIVING AND LEARNING TOGETHER

Patient Education. intermountainhealthcare.org. A Guide to Prenatal Testing LIVING AND LEARNING TOGETHER Patient Education intermountainhealthcare.org A Guide to Prenatal Testing LIVING AND LEARNING TOGETHER Most news is good news. Most babies are born without major birth defects. Early in your pregnancy,

More information

Policy Clinical Guideline Management of Women with a Low PAPP-A and Normal Chromosomes

Policy Clinical Guideline Management of Women with a Low PAPP-A and Normal Chromosomes Policy Clinical Guideline Management of Women with a Low PAPP-A and Normal Chromosomes Policy developed by: SA Maternal & Neonatal Community of Practice Approved SA Health Safety & Quality Strategic Governance

More information

Billing Guidelines for Obstetrical Services and PCO Responsibilities

Billing Guidelines for Obstetrical Services and PCO Responsibilities Billing Guidelines for Obstetrical Services and PCO Responsibilities Providing obstetrical services to UnitedHealthcare Community Plan members and your patients is a collaborative effort. Complying with

More information

The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands

The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands FVV in ObGyn, 2014, 6 (1): 7-12 Preliminary report The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands P.J. Willems 1, H. Dierickx 1, ES. Vandenakker

More information

Controversy: Is IVF Associated with Increased Rate of Birth Defect

Controversy: Is IVF Associated with Increased Rate of Birth Defect Controversy: Is IVF Associated with Increased Rate of Birth Defect R 5 謝佳琳 In Vitro Fertilization as Associated with an Increase in Major Birth Defects Christine K. Olson, M.D Division of Reproductive

More information

Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions

Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although

More information

Patient information on soft markers

Patient information on soft markers Patient information on soft markers Before you read this section remember the following important points. The vast majority of babies with soft markers are normal. Soft markers are frequently seen in healthy

More information

THE USE OF FIRST TRIMESTER ULTRASOUND

THE USE OF FIRST TRIMESTER ULTRASOUND SOGC CLINICAL PRACTICE GUIDELINES THE USE OF FIRST TRIMESTER ULTRASOUND This guideline has been reviewed by the Diagnostic Imaging Committee and approved by the Executive and Council of the Society of

More information

Trisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome)

Trisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome) Trisomies 13 and 18 (Patau and Edward s syndrome) Trisomy 21 (Down syndrome) is the commonest chromosomal disorder at birth, and has been considered in detail in previous annual reports 23. Other relatively

More information

A. Evidence for an individually adjustable standard to assess birth weight:

A. Evidence for an individually adjustable standard to assess birth weight: Customised antenatal growth charts are designed to facilitate better supervision of fetal growth. The chart is printed out in early pregnancy, after confirmation of pregnancy dates, and allows serial plotting

More information

Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester

Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester Peter M. Doubilet, MD, PhD, Carol B. Benson, MD, Jeanne S. Chow, MD Slow embryonic heart rates

More information

SIXTY-THIRD WORLD HEALTH ASSEMBLY A63/10 Provisional agenda item April Birth defects. Report by the Secretariat

SIXTY-THIRD WORLD HEALTH ASSEMBLY A63/10 Provisional agenda item April Birth defects. Report by the Secretariat SIXTY-THIRD WORLD HEALTH ASSEMBLY A63/10 Provisional agenda item 11.7 1 April 2010 Birth defects Report by the Secretariat 1. The report aims to inform the discussion on birth defects, including definition,

More information

Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System

Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System TERATOLOGY 64:S20 S25 (2001) Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System MATHIAS B. FORRESTER AND RUTH D. MERZ* Hawaii Birth Defects Program, Honolulu, Hawaii 96817 ABSTRACT

More information

Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities

Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities CME Article Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities Deniz Oztekin, MD, Ozgur Oztekin, MD, Fatma I. Aydal, MD, Sivekar Tinar, MD, Zehra H. Adibelli, MD Objective. The purpose

More information

Executive summary. Current prenatal screening

Executive summary. Current prenatal screening Executive summary Health Council of the Netherlands. NIPT: dynamics and ethics of prenatal screening. The Hague: Health Council of the Netherlands, 2013; publication no. 2013/34. In recent years, new tests

More information

Multiple Pregnancies: Determining Chorionicity and Amnionicity

Multiple Pregnancies: Determining Chorionicity and Amnionicity Thomas Jefferson University Jefferson Digital Commons Department of Radiologic Sciences Faculty Papers Department of Radiologic Sciences January 2006 Multiple Pregnancies: Determining Chorionicity and

More information

A test your patients can trust.

A test your patients can trust. A test your patients can trust. A simple, safe, and accurate non-invasive prenatal test for early risk assessment of Down syndrome and other conditions. informaseq Prenatal Test Simple, safe, and accurate

More information

Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma

Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma No. 287, February 2013 Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma This committee opinion has been prepared by

More information

Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy

Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy Testing and pregnancy GP s role 3 Counselling before and during pregnancy 3 Collecting the family history

More information

MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA

MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA Scuola di specializzazione in Genetica Medica Journal Club 14 gennaio 2014 MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA Bianchi, Diana W. MD; Prosen,

More information

Nasal bone assessment in fetuses with trisomy 21 at 16 24 weeks of gestation by three-dimensional ultrasound

Nasal bone assessment in fetuses with trisomy 21 at 16 24 weeks of gestation by three-dimensional ultrasound DOI: 10.1002/pd.2938 ORIGINAL ARTICLE Nasal bone assessment in fetuses with trisomy 21 at 16 24 weeks of gestation by three-dimensional ultrasound Nicola Persico 1,2 *, Francisca Molina 3, Guillermo Azumendi

More information

SWISS SOCIETY OF NEONATOLOGY. Umbilical cord complications in two subsequent pregnancies

SWISS SOCIETY OF NEONATOLOGY. Umbilical cord complications in two subsequent pregnancies SWISS SOCIETY OF NEONATOLOGY Umbilical cord complications in two subsequent pregnancies June 2006 2 Hetzel PG, Godi E, Bührer C, Department of Neonatology (HPG, BC), University Children s Hospital, Basel,

More information

Fetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis

Fetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis Original Paper Received: August 22, 2013 Accepted after revision: September 17, 2013 Published online: December 7, 2013 Pregnancies Using Directed Cell-Free DNA Analysis Craig A. Struble a Argyro Syngelaki

More information

Birth defects. Report by the Secretariat

Birth defects. Report by the Secretariat EXECUTIVE BOARD EB126/10 126th Session 3 December 2009 Provisional agenda item 4.7 Birth defects Report by the Secretariat 1. In May 2009 the Executive Board at its 125th session considered an agenda item

More information

Non-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application

Non-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application Non-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application PD Dr. rer. nat. Markus Stumm Zentrum für Pränataldiagnostik Kudamm-199

More information

AUSTRALIA AND NEW ZEALAND FACTSHEET

AUSTRALIA AND NEW ZEALAND FACTSHEET AUSTRALIA AND NEW ZEALAND FACTSHEET What is Stillbirth? In Australia and New Zealand, stillbirth is the death of a baby before or during birth, from the 20 th week of pregnancy onwards, or 400 grams birthweight.

More information

CONGENITAL HEART DISEASE

CONGENITAL HEART DISEASE CONGENITAL HEART DISEASE Introduction Congenital heart disease (CHD) is the most common congenital disorder in newborns [1]. Due to definitional issues, there are large variations in prevalence estimates.

More information

11 13 +6 Weeks Scan Project Newsletter

11 13 +6 Weeks Scan Project Newsletter USA FETAL MEDICINE FOUNDATION OF THE UNITED STATES OF A MERICA Non-profit Registration No.1635069 July 2007 11 13 +6 Weeks Scan Project Naomi Greene MPH RDMS RDCS 3940 Laurel Canyon Blvd. #838 Studio City,

More information

Best Second Trimester Sonographic Markers for the Detection of Trisomy 21

Best Second Trimester Sonographic Markers for the Detection of Trisomy 21 Best Second Trimester Sonographic Markers for the Detection of Trisomy 21 Patrizia Vergani, MD, Anna Locatelli, MD, Maria Giovanna Piccoli, MD, Patrizia Ceruti, MD, Eloisa Mariani, MD, John C. Pezzullo,

More information

First-trimester screening markers are altered in pregnancies conceived after IVF/ICSI

First-trimester screening markers are altered in pregnancies conceived after IVF/ICSI Ultrasound Obstet Gynecol 2009; 33: 8 17 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.6254 First-trimester screening markers are altered in pregnancies conceived

More information

Preimplantation Genetic Diagnosis (PGD) in Western Australia

Preimplantation Genetic Diagnosis (PGD) in Western Australia Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome

More information

Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA

Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions

More information

Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy

Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy This statement has been

More information

Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11 13 weeks

Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11 13 weeks PRENATAL DIAGNOSIS Prenat Diagn 2011; 31: 66 74. Published online in Wiley Online Library (wileyonlinelibrary.com).2660 Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical

More information

The California Prenatal Screening Program

The California Prenatal Screening Program The California Prenatal Screening Program Quad Marker Screening One blood specimen drawn at 15 weeks - 20 weeks of pregnancy (second trimester) Serum Integrated Screening Prenatal Patient Booklet - English

More information

Triploidy. rarechromo.org

Triploidy. rarechromo.org Triploidy rarechromo.org Triploidy Triploidy is a disorder that arises at conception when a baby starts life in the womb with a complete extra set of chromosomes. Chromosomes are the microscopically small

More information

Noninvasive prenatal screen for pregnancy

Noninvasive prenatal screen for pregnancy Noninvasive prenatal screen for pregnancy What is QNatal TM Advanced Noninvasive Prenatal Screening? The QNatal Advanced prenatal screen is a noninvasive test that provides a high degree of accuracy for

More information

A Guide to Prenatal Genetic Testing

A Guide to Prenatal Genetic Testing Patient Education Page 29 A Guide to Prenatal Genetic Testing This section describes prenatal tests that give information about your baby s health. It is your choice whether or not to have these tests

More information

IBGRL, NHSBT, Bristol

IBGRL, NHSBT, Bristol IBGRL, NHSBT, Bristol Valuable to know D type of fetus Fetus D-positive: at risk pregnancy should be managed appropriately Fetus D-negative: not at risk no need for intervention RHD RHCE RHD* D 37 bp

More information

INDICATIONS FOR USE OF ANTI-D IMMUNOGLOBULIN

INDICATIONS FOR USE OF ANTI-D IMMUNOGLOBULIN The Guidelines for use of Anti-D Immunoglobulin have been prepared by NZ Blood Service for use by Midwives and Medical Practitioners involved in caring for pregnancies or obstetric practice in New Zealand.

More information

Down s Syndrome: Ultrasound Screening

Down s Syndrome: Ultrasound Screening October 2001 Down s Syndrome: Ultrasound Screening Hilary Hochberg Advanced Radiology Clerkship Dr. Gillian Lieberman Patient M.C. 32 year old female presents at 16 weeks gestational age with abnormal

More information

Fetal size and dating: charts recommended for clinical obstetric practice

Fetal size and dating: charts recommended for clinical obstetric practice Fetal size and dating: charts recommended for clinical obstetric practice Pam Loughna 1, Lyn Chitty 2, Tony Evans 3 & Trish Chudleigh 4 1 Academic Division of Obstetrics and Gynaecology, Nottingham University

More information

2013 National Comparative Audit of Anti-D Ig Prophylaxis. M Rowley, T Davies, T Hawkins, J Hibbert and J Grant-Casey

2013 National Comparative Audit of Anti-D Ig Prophylaxis. M Rowley, T Davies, T Hawkins, J Hibbert and J Grant-Casey 2013 National Comparative Audit of Anti-D Ig Prophylaxis M Rowley, T Davies, T Hawkins, J Hibbert and J Grant-Casey The National Comparative Audit Programme A series of audits designed to look at the use

More information

Prognosis of Very Large First-Trimester Hematomas

Prognosis of Very Large First-Trimester Hematomas Case Series Prognosis of Very Large First-Trimester Hematomas Juliana Leite, MD, Pamela Ross, RDMS, RDCS, A. Cristina Rossi, MD, Philippe Jeanty, MD, PhD Objective. The aim of this study was to evaluate

More information

Parvovirus B19 Infection in Pregnancy

Parvovirus B19 Infection in Pregnancy Parvovirus B19 Infection in Pregnancy Information Pack Parvovirus B19 Infection in Pregnancy Information Booklet CONTENTS: THE VIRUS page 3 CLINICAL MANIFESTATIONS page 6 DIAGNOSIS page 8 PATIENT MANAGEMENT

More information

Department of Obstetrics and Gynecology, Kayseri Military Hospital, Kayseri, Turkey

Department of Obstetrics and Gynecology, Kayseri Military Hospital, Kayseri, Turkey Orıgınal Article Obstetrics & Gynecology North Clin Istanbul 2015;2(2):92-100 doi: 10.14744/nci.2015.08370 A prospective study to assess the clinical impact of interobserver reliability of sonographic

More information

a new era in prenatal testing

a new era in prenatal testing TM a new era in prenatal testing TM What is? Non-Invasive Prenatal Testing (NIPT) represents a major advance in screening and risk assessment for chromosomal abnormalities. In January 2016, the UK National

More information

Crohn's disease and pregnancy.

Crohn's disease and pregnancy. Gut, 1984, 25, 52-56 Crohn's disease and pregnancy. R KHOSLA, C P WILLOUGHBY, AND D P JEWELL From the Gastroenterology Unit, Radcliffe Infirmary, Oxford SUMMARY Infertility and the outcome of pregnancy

More information

COMMITTEE OPINION. Cell-free DNA Screening for Fetal Aneuploidy

COMMITTEE OPINION. Cell-free DNA Screening for Fetal Aneuploidy The American College of Obstetricians and Gynecologists WOMEN S HEALTH CARE PHYSICIANS (Published Electronically Ahead of Print on June 26, 2015) COMMITTEE OPINION Number 640 September 2015 (This Committee

More information

Information on the anomaly scan

Information on the anomaly scan Information on the anomaly scan The 20-week ultrasound August 2014 2 Contents 1. What can I find in this brochure? 5 2. Screening for physical defects 7 3. Abnormal test results 8 4. Making a conscious

More information

journal of medicine The new england DNA Sequencing versus Standard Prenatal Aneuploidy Screening ABSTRACT

journal of medicine The new england DNA Sequencing versus Standard Prenatal Aneuploidy Screening ABSTRACT The new england journal of medicine established in 1812 february 27, 2014 vol. 370 no. 9 DNA Sequencing versus Standard Prenatal Aneuploidy Screening Diana W. Bianchi, M.D., R. Lamar Parker, M.D., Jeffrey

More information